The case was filed in connection with the submission of abbreviated new drug application (ANDA) for Frovatriptan Succinate EQ, 2.5mg base tablets with the US Food and Drug Administration (FDA).
Mylan‘s Frovatriptan Succinate EQ, 2.5mg base tablets are generic equivalent to Endo Pharma’s Frova which is used as a treatment of symptoms related to acute migraine headaches with or without aura, in adults.